BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET
Company Participants
Vimal Mehta - Chief Executive Officer & Founder
Richard Steinhart - Senior Vice President and Chief Financial Officer
Matt Wiley - Chief Commercial Officer
Robert Risinger - Chief Medical Officer, Neuroscience
Frank Yocca - Chief Scientific Officer
Vincent O’Neill - Senior Vice President & Chief Medical Officer, Oncology
Conference Call Participants
Greg Harrison - Bank of America
Robyn Karnauskas - Truist Securities
Sumant Kulkarni - Canaccord
Colin Bristow - UBS
Richard Allen - Mizuho Securities
Ram Selvaraju - H.C. Wainwright
Corinne Jenkins - Goldman Sachs
Operator
Good morning and welcome to the BioXcel Therapeutics Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] After the presentation, there will be a question-and-answer session. [Operator Instructions] Just to remind everyone, certain matters discussed in today's conference call and/or answers that may be given to questions asked are forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company.
Actual results could differ materially from those anticipated in these forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended March 31, 2021 which can be found at www.BioXceltherapeutics.com or on www.sec.gov, which will be updated in its quarterly report on Form 10-Q for the quarter ended June 30, 2022. As a reminder, today's conference is being recorded.
Joining us on today's call are Dr. Vimal Mehta, Chief Executive Officer; Richard Steinhart, Chief Financial Officer; Matt Wiley, Chief Commercial Officer; Dr. Rob Risinger, Chief Medical Officer of Neuroscience; Dr. Frank Yocca, Chief Scientific Officer; and Dr. Vince O’Neill, Chief Medical Officer of Oncology.
It is now my pleasure to turn the call over to Dr. Mehta, the CEO of BioXcel Therapeutics. Please go ahead.
Vimal Mehta
Thank you, operator. Welcome everyone and thank you for joining our call today to discuss BioXcel Therapeutics financial performance and business highlights for the second quarter of 2022. It has been a busy but rewarding few months. And we have been -- we have many exciting updates to review this morning. As you know, we are a biopharmaceutical company utilizing Artificial Intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
You have heard me discuss our five year vision to become the premier AI driven neuroscience company and our progress from this past quarter across all parts of our business continues to bring us closer to this ambitious goal. Let me begin by highlighting our notable achievements across the organization. We have laid the foundation for a successful entry into the market for IGALMI, our FDA approved acute treatment for mild, moderate or severe agitation associated with bipolar I or II disorder or schizophrenia in adults.